Allogeneic blood-based therapies: hype or hope?

doi:10.1038/eye.2016.268

. 2017 Apr;31(4):509-510.

doi: 10.1038/eye.2016.268. Epub 2016 Dec 2.

Allogeneic blood-based therapies: hype or hope?

E Anitua^{1

2}, M de la Fuente², J Merayo-Lloves³, F Muruzabal², G Orive^{1

2

4

5}

Affiliations

¹ Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain.
² Research and Development, BTI - Biotechnology Institute, Vitoria, Spain.
³ Instituto Universitario Fernández-Vega, Universidad de Oviedo, Oviedo, Spain.
⁴ Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain.
⁵ Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, SLFPB-EHU, Vitoria, Spain.

PMID: 27911449
PMCID: PMC5395995
DOI: 10.1038/eye.2016.268

Allogeneic blood-based therapies: hype or hope?

E Anitua et al. Eye (Lond). 2017 Apr.

. 2017 Apr;31(4):509-510.

doi: 10.1038/eye.2016.268. Epub 2016 Dec 2.

Authors

E Anitua^{1

2}, M de la Fuente², J Merayo-Lloves³, F Muruzabal², G Orive^{1

2

4

5}

Affiliations

¹ Eduardo Anitua Foundation for Biomedical Research, Vitoria, Spain.
² Research and Development, BTI - Biotechnology Institute, Vitoria, Spain.
³ Instituto Universitario Fernández-Vega, Universidad de Oviedo, Oviedo, Spain.
⁴ Laboratory of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, University of the Basque Country, Vitoria, Spain.
⁵ Networking Biomedical Research Center on Bioengineering, Biomaterials and Nanomedicine, CIBER-BBN, SLFPB-EHU, Vitoria, Spain.

PMID: 27911449
PMCID: PMC5395995
DOI: 10.1038/eye.2016.268

No abstract available

PubMed Disclaimer

Conflict of interest statement

The authors declare that EA is the Scientific Director and MDlF, GO and FM are scientists at BTI Biotechnology Institute, a dental implant company that investigates in the fields of oral implantology and PRGF-Endoret technology.

Cited by

Blood-Based Treatments for Severe Dry Eye Disease: The Need of a Consensus.
Bernabei F, Roda M, Buzzi M, Pellegrini M, Giannaccare G, Versura P. Bernabei F, et al. J Clin Med. 2019 Sep 17;8(9):1478. doi: 10.3390/jcm8091478. J Clin Med. 2019. PMID: 31533289 Free PMC article. Review.
Use of allogeneic platelet-rich plasma for the treatment of autoimmune ocular surface disorders: case series.
Mancini M, Postorino EI, Gargiulo L, Aragona P. Mancini M, et al. Front Ophthalmol (Lausanne). 2023 Oct 5;3:1215848. doi: 10.3389/fopht.2023.1215848. eCollection 2023. Front Ophthalmol (Lausanne). 2023. PMID: 38983003 Free PMC article.

References

1. Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol 2015; 93(8): e605–e614. - PubMed
1. Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond) 2009; 23(2): 290–293. - PubMed
1. Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 2012; 28(5): 479–483. - PMC - PubMed
1. Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013; 104(3): 183–199. - PubMed
1. Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res 2014; 119: 27–34. - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations
Medical
- MedlinePlus Consumer Health Information
- MedlinePlus Health Information

[1] Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol 2015; 93(8): e605–e614. - PubMed

[2] Anitua E, Muruzabal F, Tayebba A, Riestra A, Perez VL, Merayo-Lloves J et al. Autologous serum and plasma rich in growth factors in ophthalmology: preclinical and clinical studies. Acta Ophthalmol 2015; 93(8): e605–e614. - PubMed

[3] Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond) 2009; 23(2): 290–293. - PubMed

[4] Chiang CC, Chen WL, Lin JM, Tsai YY. Allogeneic serum eye drops for the treatment of persistent corneal epithelial defect. Eye (Lond) 2009; 23(2): 290–293. - PubMed

[5] Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 2012; 28(5): 479–483. - PMC - PubMed

[6] Na KS, Kim MS. Allogeneic serum eye drops for the treatment of dry eye patients with chronic graft-versus-host disease. J Ocul Pharmacol Ther 2012; 28(5): 479–483. - PMC - PubMed

[7] Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013; 104(3): 183–199. - PubMed

[8] Prowse CV. Component pathogen inactivation: a critical review. Vox Sang 2013; 104(3): 183–199. - PubMed

[9] Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res 2014; 119: 27–34. - PubMed

[10] Anitua E, Muruzabal F, De la Fuente M, Merayo-Lloves J, Orive G. Effects of heat-treatment on plasma rich in growth factors-derived autologous eye drop. Exp Eye Res 2014; 119: 27–34. - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Allogeneic blood-based therapies: hype or hope?

Affiliations

Allogeneic blood-based therapies: hype or hope?

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Other Literature Sources

Medical